Isomorphic Labs, the London-based drug discovery company that spun out of Google DeepMind in 2021, said on Tuesday that it has raised a $5 billion Series C co-led by Greenoaks and Sequoia Capital. The announcement, made on 17 November 2026, comes roughly six months after the company disclosed a $2.1 billion Series B on 12 May 2026, putting two rounds totaling $7.1 billion on the board inside a single half-year. The company did not disclose a valuation for the new round.
Who put in the money
Greenoaks and Sequoia Capital co-led the Series C, with Andreessen Horowitz (a16z) and several other new investors joining, according to Isomorphic Labs. The company also described continued significant investment from Alphabet, which it framed separately from its roster of returning backers.
Those existing investors all participated, the company said: Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. That combination of crossover growth funds, sovereign capital, and corporate venture arms tells vendors something practical about the buyer: the company has deep-pocketed institutional owners who tend to expect spending to be documented and defensible. For teams tracking how capital is pooling across AI startups and applied science companies, the syndicate is as notable as the headline number.
TechCrunch noted that the new Series C comes on the heels of the May round. With no valuation disclosed for the Series C, operators should resist pricing assumptions in their outreach.
What Isomorphic Labs is building
Isomorphic Labs designs and develops new medicines with AI, and its work builds on AlphaFold, the protein structure prediction research that came out of Google’s DeepMind. The company is scaling IsoDDE, its proprietary drug design engine, along with its pipeline of AI-designed therapeutic candidates.
TechCrunch reported that the work has produced positive preclinical results in oncology and immunology, and that the company has struck deals with Eli Lilly, Novartis, and Johnson & Johnson. TechCrunch also described the company’s intent to take its drug candidates to clinical trials, and said the funding will support continued development of the drug-design engine along with a foray into more types of medicine.
Vendors selling into biotech startups and funded pharma startups should keep in mind that a computational platform, a therapeutic candidate pipeline, and pharmaceutical partnerships each tend to carry their own procurement pattern, with different buyers and different review cycles.
What the raise means for vendors
A $5 billion round of this type usually converts into headcount, compute, lab capacity, and the compliance scaffolding that regulated drug development demands. Vendors selling into London startups and London AI startups should expect demand across research computing infrastructure, data engineering, laboratory information systems, quality and regulatory documentation tooling, and the scientific and engineering recruiting that staffs all of it.
Partnership structures with large pharmaceutical companies raise the bar on security review, data governance, and auditability, so sellers who can speak to those requirements will clear diligence faster than those leading with feature lists. Teams mapping the broader market of UK startups, including recent British AI funding such as Fractile’s $720 million Series C, should also watch the downstream effect: capital at this size tends to pull service providers, contract research organizations, and specialist talent toward the companies writing the checks.
Timing matters. Budget cycles after a raise this large typically open over the following quarters rather than immediately, and the most effective approach is to track the hiring and infrastructure signals that recently funded startups broadcast before they formally open procurement.
The same week, Redwood City-based Galvanize Therapeutics raised a $130 million Series D led by HealthQuest Capital, after passing 4,000 Aliya procedures.
Free: top-10 + totals • Paid: full list + verified contacts
This is free coverage of a funding event. Growth and Scale unlock every newly funded company we track each week, plus verified decision-maker contacts.
Sources: Isomorphic Labs, 17 November 2026; TechCrunch; Isomorphic Labs Series B, 12 May 2026. Featured image: the London skyline from Waterloo Bridge, by Diliff / Wikimedia Commons, CC BY-SA 3.0, via Wikimedia Commons.